Du är här:

Pharmaceutical reviews

We regularly review the reimbursement status of medicines to see if they should remain in the reimbursement system or not.

We are reviewing individual medicines or smaller groups of medicines, within areas where we judge there to be greatest reason to question whether the medicine provides cost-effective utility. The balance between medicines cost effective utility changes though over time when for example new medicines are included in the high-cost threshold or when we accept new pricing for a medicine.

Prior to commencing a new review we make detailed prioritization analyses where we, in part, look at sales volumes, reimbursement costs, cost per DDD, expanded indications and expired patents. We also hold a dialogue with the county councils and provide them with an opportunity to submit suggestions on which products we should review.

We may also start a review in connection with evaluating an application for a new medicine to be part of the reimbursement system. We start a review like this if there are deficiencies in the area when it comes to usage or cost-effectiveness.

Publicerad 11 september 2017
Uppdaterad 08 november 2017


Måndag- fredag
09:00 - 16:00.

Växel: 09:00 -16:00.
Registratur:  09:00 -15:00.



Telefon växel: 08 - 568 420 50

08 568 420 99

http://www.tlv.se/länk till annan webbplats, öppnas i nytt fönster

Fleminggatan 18
112 26 Stockholm

Tandvårds- och läkemedelsförmånsverket
Box 225 20
104 22 Stockholm

FE 909
838 74 Frösön

202 100 - 5364


Följ TLV

Följ på twitter

Följ på LinkedIn